Biosimilars: Not simply generics

Celia Lu, Elsen C. Jacob

Research output: Contribution to specialist publicationArticle

5 Scopus citations

Abstract

With the entry of biosimilars into the U.S. market, it is important for pharmacists to understand these products and how they differ from generic medications. Unlike generics, biosimilars are not identical to the reference biological product. Because biological products are made using living cells and processes, they may have minor differences from the reference product. For approval, biosimilars must demonstrate that these differences are not clinically meaningful. Nonetheless, certain factors should be considered when a switch from the reference product to a biosimilar is contemplated. For this reason, pharmacists have an opportunity to educate patients and providers to ensure appropriate use.

Original languageEnglish
Pages36-49
Number of pages14
Volume44
No6
Specialist publicationU.S. Pharmacist
StatePublished - Jun 2019
Externally publishedYes

Fingerprint

Dive into the research topics of 'Biosimilars: Not simply generics'. Together they form a unique fingerprint.

Cite this